Partnering with General practitioners to Optimise Survivorship for PatiEnts with Lymphoma: A Phase II randomised controlled trial.

Not Applicable

Active, not recruiting

• Conditions: ymphoma; Lymphoma; Cancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma; Cancer - Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma; Cancer - Hodgkin's

• Registration Number: ACTRN12620000594921
• Lead Sponsor: Professor Raymond Chan

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-05-22
• Last Update Posted: 9 August 2022

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

Due to the varying follow-up requirements for patients with lymphoma, we will recruit 2 groups of patients who map to 2 distinct follow-up pathways:
-Group 1. Acute post-treatment follow-up: Patients with a pathologically confirmed diagnosis of aggressive or indolent lymphoma in the acute post-treatment phase (i.e., within three months of completion of chemotherapy); and
-Group 2. Observation follow-up (i.e., surveillance clinics): Patients with a pathologically confirmed diagnosis of indolent lymphoma followed up in the surveillance clinic and at least 2 years post-treatment or treatment naïve.

All participants must be:
-Men or women
->/=18 years of age
-have an ECOG performance status <2
-be an ambulatory patient at the time of recruitment
-be able to nominate a GP to be involved in their follow-up
-have access to a telephone

Exclusion Criteria

-the presence of severe mental, cognitive or physical conditions that would limit the patient’s ability to participate as per treating clinician.
-Lymphoma not in remission

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Health-related quality of life as measured by Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym)[Measured at baseline, 6 months and 12 months.]